New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a study 1 that highlights the development and validation of a breast cancer polygenic risk score (PRS) for women of all ancestries
SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a study 1 that highlights the development and validation of a breast cancer polygenic risk score (PRS) for women of all ancestries.
“PRS is one of the most powerful risk prediction tools in the field of breast cancer, and until recently a validated model had not been available to assess women of all ancestries,” said Dr. Holly Pederson, Director of Medical Breast Services at Cleveland Clinic. “Our new methodology provides a framework for a recalibrated PRS that delivers a personalized genomic breast cancer risk assessment to all women.”
The study -- first presented in an oral presentation at the 2021 ASCO Annual Meeting by Dr. Peterson – examined data from more than 275,000 women of diverse ancestral backgrounds to validate a novel method for assessing breast cancer PRS by using ancestry-informative genetic markers.
Results showed the new method of risk scoring was more accurate for women of all ancestries, indicating that weighting risk based on genetic ancestry will make it possible to deliver more reliable results to all women. Myriad has already incorporated the enhancement into the commercial offering of its MyRisk™ Hereditary Cancer Test with RiskScore®.
RiskScore is the first risk prediction model that combines a PRS validated for women of all ancestries with clinical and biological variables. It provides a five-year and lifetime risk assessment of developing breast cancer for women who qualify for MyRisk.
“The findings represent an important step forward to improve patient outcomes by expanding access and reducing healthcare disparities in genetic testing and breast cancer risk assessment,” said Thomas Slavin, MD, Chief Medical Officer, Myriad Genetics. “More women will be able to benefit from knowing their genomically informed risk of developing breast cancer and work with their physicians on how to best manage that risk.”
1 Hughes et al. JCO Precision Oncology 2022 (https://ascopubs.org/doi/abs/10.1200/PO.22.00084)
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating a breast cancer polygenic risk score for women of all ancestries and the benefits for women of knowing their genomically informed risk of developing breast cancer. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Megan Manzari
(385) 318-3718
Megan.Manzari@myriad.com
Investor Contact:
Matt Scalo
(801) 584-532
Matt.Scalo@myriad.com
